[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340227-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340227-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","tumor-eradication-by-triplet-therapy-with-braf-inhibitor-tlr-7-agonist-and-pd-1-antibody-for-braf-mutated-melanoma","Tumor eradication by triplet therapy with BRAF inhibitor, TLR 7 agonist, and PD-1 antibody for BRAF-mutated melanoma","","Programmed death 1 (PD-1)/PD-L1 inhibitors are widely used to treat cancers such as melanoma, but single-agent efficacy remains limited and combination approaches are actively investigated. This study evaluates triplet immunotherapy combining an anti-PD-1 antibody with a BRAF inhibitor and a Toll-like receptor 7 agonist. In human BRAF-mutated melanoma xenografts, vemurafenib restored dendritic-cell T-cell stimulatory activity by reducing melanoma-derived immunosuppressive cytokines including interleukin 6. TLR7 agonist DSR6434 further enhanced vemurafenib-mediated tumor inhibition via plasmacytoid dendritic cell/interferon-α/natural killer and conventional dendritic cell T-cell stimulation pathways. In syngeneic models, the vemurafenib–DSR6434 combination synergistically increased gp100-specific T-cell induction and suppressed tumor growth, while only the full triplet plus anti-PD-1 achieved complete regression in a CD8 T-cell-dependent manner.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/tumor-eradication-by-triplet-therapy-with-braf-inhibitor-tlr-7-agonist-and-pd-1-antibody-for-braf-mutated-melanoma/340227/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/tumor-eradication-by-triplet-therapy-with-braf-inhibitor-tlr-7-agonist-and-pd-1-antibody-for-braf-mutated-melanoma/340227.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are anti-PD-1 therapies not fully effective as monotherapy for melanoma?","Question",{"text":63,"@type":64},"Response rates to anti-PD-1 antibodies are limited (about 20%–40% in melanoma), motivating the exploration of combination immunotherapies to improve outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What are the three agents used in the triplet therapy evaluated in this study?",{"text":68,"@type":64},"The triplet therapy combines an anti-PD-1 antibody with a BRAF inhibitor and a Toll-like receptor 7 agonist (DSR6434) to target adaptive and primary immune resistance mechanisms and enhance innate immune responses.",{"name":70,"@type":61,"acceptedAnswer":71},"What key immunological effects did vemurafenib and DSR6434 produce in mouse models?",{"text":72,"@type":64},"Vemurafenib reduced melanoma-derived immunosuppressive cytokines (including IL-6) and restored conventional dendritic-cell T-cell stimulatory activity. DSR6434 enhanced tumor growth inhibition through plasmacytoid dendritic cell/interferon-α/natural killer pathways and boosted dendritic-cell-mediated T-cell stimulation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340227,1790104602,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Received: 19 December 2023 | Revised: 14 May 2024 | Accepted: 2 June 2024  \nDOI: 10. 1111/cas.16251  \nOR I G I NAL ART I C L E  \nTumor eradication by triplet therapy with BRAF inhibitor, TLR 7 agonist, and PD-1 antibody for BRAF-mutated melanoma  \nKenta Nakamura1,2  | Tomonori Yaguchi1,3 | Masashi Murata4 | Yosuke Ota4 | Asuka Mikoshiba2 | Yukiko Kiniwa2 | Ryuhei Okuyama2 | Yutaka Kawakami1,5  \n1Division of Cellular Signaling, Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan 2Department of Dermatology, Shinshu University School of Medicine, Nagano, Japan  \n3 Department of Immunology and Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan 4Cancer Research Unit, Sumitomo Pharma Co. Ltd. , Osaka, Japan  \n5Department of Immunology, School of Medicine, International University of Health and Welfare, Chiba, Japan  \nCorrespondence  \nYutaka Kawakami, Department of Immunology, School of Medicine, International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba 286-8686, Japan. [Email:](Email: yutakawa@iuhw.ac.jp)[ yutakawa@iuhw.ac.jp](Email: yutakawa@iuhw.ac.jp), yutakawa@ [keio.jp](keio.jp)  \nKenta Nakamura, Department of Dermatology, School of Medicine, Shinshu University, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan.  \nEmail: [kenta1983@shinshu-u.ac.jp](kenta1983@shinshu-u.ac.jp)  \nFunding information  \nMinistry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, Grant/Award Number: 26221005; Japan Agency for Medical Research and Development (AMED), Grant/Award Number: 16cm0106305h0001; Project for Cancer Research and Therapeutic Evolution (P-CREATE), Grant/Award Number: 15cm0106084h0005; Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT), Grant/ Award Number: 15sk0210034h0001  \nAbstract  \nProgrammed death 1 (PD-1)/programmed death-ligand 1 inhibitors are commonly used to treat various cancers, including melanoma. However, their efficacy as monotherapy is limited, and combination immunotherapies are being explored to improve outcomes. In this study, we investigated a combination immunotherapy involving an anti-PD-1 antibody that blocks the major adaptive immune-resistant mechanisms, a BRAF inhibitor that inhibits melanoma cell proliferation, and multiple primary immune-resistant mechanisms, such as cancer cell-derived immunosuppressive cytokines, and a Toll-like receptor 7 agonist that enhances innate immune responses that promote antitumor T-cell induction and functions. Using axenogeneic nude mouse model implanted with human BRAF-mutated melanoma, a BRAF inhibitor vemurafenib was found to restore T-cell-stimulatory activity in conventional dendritic cells by reducing immunosuppressive cytokines, including interleukin 6, produced by human melanoma. Additionally, intravenous administration of the Toll-like receptor 7 agonist DSR6434 enhanced tumor growth inhibition by vemurafenib through stimulating the plasmacytoid dendritic cells/interferon-α/ natural killer cell pathways and augmenting the T-cell-stimulatory activity of conventional dendritic cells. In a syngeneic mouse model implanted with murine BRAFmutated melanoma, the vemurafenib and DSR6434 combination synergistically augmented the induction of melanoma antigen gp100-specific T cells and inhibited tumor growth. Notably, only triplet therapy with vemurafenib, DSR6434, and the anti-PD-1 antibody resulted in complete regression of SIY antigen-transduced  \nAbbreviations: ELISA, enzyme-linked immunosorbent assay; IFN, interferon; MAPK, mitogen-activated protein kinase; MHC, major histocompatibility complex; NK, natural killer; PD-1, programmed death 1; TLR7, Toll-like receptor 7; VEGF, vascular endothelial growth factor.  \nKenta Nakamura and Tomonori Yaguchi contributed equally to this work.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any me","cbCaiuzVVdlNJ1BO","https://ap.wps.com/l/cbCaiuzVVdlNJ1BO","pdf",8630693,14,"English","# Abstract\n## Introduction\n## Combination immunotherapy rationale","[{\"question\":\"Why are anti-PD-1 therapies not fully effective as monotherapy for melanoma?\",\"answer\":\"Response rates to anti-PD-1 antibodies are limited (about 20%–40% in melanoma), motivating the exploration of combination immunotherapies to improve outcomes.\"},{\"question\":\"What are the three agents used in the triplet therapy evaluated in this study?\",\"answer\":\"The triplet therapy combines an anti-PD-1 antibody with a BRAF inhibitor and a Toll-like receptor 7 agonist (DSR6434) to target adaptive and primary immune resistance mechanisms and enhance innate immune responses.\"},{\"question\":\"What key immunological effects did vemurafenib and DSR6434 produce in mouse models?\",\"answer\":\"Vemurafenib reduced melanoma-derived immunosuppressive cytokines (including IL-6) and restored conventional dendritic-cell T-cell stimulatory activity. DSR6434 enhanced tumor growth inhibition through plasmacytoid dendritic cell/interferon-α/natural killer pathways and boosted dendritic-cell-mediated T-cell stimulation.\"}]","Tumor eradication by triplet therapy with BRAF inhibitor, TLR 7 agonist, and PD-1 antibody for BRAF-mutated melanoma | PDF",1790035053,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f15532fff832ff833e4fd11e63b6623.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4491f3e2e6f9a09164140033e03d131b.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/22c81358d4063e58036b5f1eca3f33a0.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10eb0154853c686f9da9f39c169ef241.webp",980,1287]